XLO: Xilio Therapeutics insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Activist and 5% holders
| Filed | What | Holder | Stake | Change | Filing |
|---|---|---|---|---|---|
| 2026-08-14 | 13G amendment | StemPoint Capital LP | 9.50% | SEC |
Institutional ownership (Q2 2026)
26 institutions reported holding $26.28M of Xilio Therapeutics on Form 13F (23 the quarter before). 11 opened a new position and 7 sold out. Shares held by institutions: +41%.
| Largest holders | Shares | Value |
|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 664,021 | $6.36M |
| ORBIMED ADVISORS LLC | 592,300 | $5.67M |
| Frazier Life Sciences Management, L.P. | 422,505 | $4.05M |
| Stonepine Capital Management, LLC | 225,994 | $2.17M |
| VANGUARD CAPITAL MANAGEMENT LLC | 178,517 | $1.71M |
| Sio Capital Management, LLC | 152,464 | $1.46M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 111,541 | $1.07M |
| Merck & Co., Inc. | 105,982 | $1.02M |
| RENAISSANCE TECHNOLOGIES LLC | 64,153 | $615K |
| MORGAN STANLEY | 56,954 | $546K |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.